Combination Products: A Difficult Balance Between Drug and Device
Combination products have made a massive impact on the healthcare landscape by offering powerful and novel treatment options and approaches. The growth rate for this products is expected to continue propelling forward.
These drug products require a particularly nuanced approach from development through delivery that is essential to ensuring optimal outcomes can be achieved.
Read our latest article, “Combination Products: A Difficult Balance Between Drug and Device”, published at European Biopharmaceutical Review, January 2023, pages 42-45. © Samedan Ltd.
In this article we have investigated what is classified as a Combination Product and what are the differences between permitted daily exposure and tolerable intake.
For more information contact us: InfoFarma@eurofins.com